In addition, TKIs, such as dasatinib and imatinib, have been reported to improve insulin sensitivity and glucose tolerance and to prevent the onset, or to lead to the remission of type 1 and type 2 diabetes in various animal models [40–45], attributed to their immunomodulatory activities and reduction of ER-stress [46,47]. This evidence concerns the gene INS and type 2 diabetes mellitus.